Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

by Nissen, Steven E. , Nicholls, Stephen J. , Balinskaite, Violeta , Kastelein, John J.P. , Harada-Shiba, Mariko , Banach, Maciej , Ballantyne, Christie M. , Curcio, Danielle L. , Kling, Douglas , Catapano, Alberico L. , Szarek, Michael , Navar, Ann Marie , Davidson, Michael H. , Nelson, Adam J. , Butters, Julie , Ditmarsch, Marc , Huo, Yong , Neild, Annie , Hsieh, Andrew , Ray, Kausik K. , Laufs, Ulrich , Mehran, Roxana , Ference, Brian A.

in Adult / Aged / Anticholesteremic Agents - administration & dosage / Anticholesteremic Agents - adverse effects / Apolipoproteins / Arteriosclerosis / Atherosclerosis / Atherosclerosis - blood / Atherosclerosis - complications / Atherosclerosis - drug therapy / Cardiology / Cardiology General / Cardiovascular disease / Cardiovascular diseases / Cardiovascular Diseases - blood / Cardiovascular Diseases - etiology / Cardiovascular Diseases - prevention & control / Cholesterol / Cholesterol Ester Transfer Proteins - antagonists & inhibitors / Cholesterol, HDL - blood / Cholesterol, LDL - blood / Cholesteryl ester transfer protein / Collaboration / Coronary vessels / Diabetes / Double-Blind Method / Enzymes / Female / Heart attacks / Heart Disease Risk Factors / Hemoglobin / High density lipoprotein / Humans / Hypercholesterolemia / Hyperlipoproteinemia Type II - blood / Hyperlipoproteinemia Type II - complications / Hyperlipoproteinemia Type II - drug therapy / Lipids / Low density lipoprotein / Male / Middle Aged / Placebos / Risk factors / Statins / Statistical analysis

2025

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

2025

Confirm

Do you wish to request the book?

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

2025

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

Nissen, Steven E.,

Nicholls, Stephen J.,

Balinskaite, Violeta,

Kastelein, John J.P.,

Harada-Shiba, Mariko,

Banach, Maciej,

Ballantyne, Christie M.,

Curcio, Danielle L.,

Kling, Douglas,

Catapano, Alberico L.,

Szarek, Michael,

Navar, Ann Marie,

Davidson, Michael H.,

Nelson, Adam J.,

Butters, Julie,

Ditmarsch, Marc,

Huo, Yong,

Neild, Annie,

Hsieh, Andrew,

Ray, Kausik K.,

Laufs, Ulrich,

Mehran, Roxana,

Ference, Brian A.

2025

Overview

In a randomized trial involving patients at high cardiovascular risk, the cholesteryl ester transfer protein inhibitor obicetrapib reduced low-density lipoprotein cholesterol levels by 29.9% at 84 days.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Anticholesteremic Agents - administration & dosage

/ Anticholesteremic Agents - adverse effects

/ Apolipoproteins

/ Arteriosclerosis

/ Atherosclerosis